

Claim Amendments

Please enter the following amendments, which include cancellation of claims 2-6, 13-16, 18-19, 21-25, 27-47, 49, 52, 58-60 and 63-71, and amendment of claims 1, 48 and 53-56.

1 (currently amended): A compound that binds to a BCL6 lateral groove and prevents binding of a corepressor to the lateral groove, wherein the compound comprises a peptide or mimetic comprising SEQ ID NO:10.

2-6 (canceled)

7 (original): The peptide or mimetic of claim 6, comprising SEQ ID NO:1.

8 (original): The peptide or mimetic of claim 6, comprising SEQ ID NO:2.

9 (original): The peptide or mimetic of claim 6, comprising SEQ ID NO:3.

10 (original): The peptide or mimetic of claim 4, having 84 or less amino acid or analog residues.

11 (original): The peptide or mimetic of claim 4, having 21 or less amino acid or analog residues.

12 (original): The peptide or mimetic of claim 4, having 17 amino acid or analog residues.

13-16 (canceled)

17 (original): The peptide or mimetic of claim 1, further comprising at least one functional group.

18-19 (canceled)

20 (original): The peptide or mimetic of claim 17, wherein the functional group is a moiety that facilitates entry of the peptide or mimetic into a cell.

21-25 (canceled)

26 (original): The compound of claim 1, in a pharmaceutically acceptable excipient.

27-47 (canceled)

48 (currently amended): A method of treating a mammal with cancer, wherein the cancer requires BCL6 repression, the method comprising administering the compound of claim ~~1~~26 to the mammal.

49 (canceled)

50 (original): The method of claim 48, wherein the cancer is a lymphoma.

51 (original): The method of claim 48, wherein the cancer is a breast cancer.

52 (canceled)

53 (currently amended): The method of claim ~~52~~48, wherein the peptide or mimetic comprises SEQ ID NO:10.

54 (currently amended): The method of claim ~~52~~48, wherein the peptide or mimetic comprises the sequence of SEQ ID NO:1.

55 (currently amended): The method of claim ~~52~~48, wherein the peptide or mimetic comprises the sequence of SEQ ID NO:2.

56 (currently amended): The method of claim ~~52~~48, wherein the peptide or mimetic comprises the sequence of SEQ ID NO:3.

57 (original): A polypeptide comprising SEQ ID NO:12.

58-60 (canceled)

61 (original): A vector comprising the polynucleotide of claim 60, capable of expressing the polypeptide.

62 (original): A method of determining whether a test compound inhibits corepressor binding to BCL6, the method comprising determining whether the test compound binds to a BCL6 lateral groove, wherein a compound that binds to a BCL6 lateral groove inhibits corepressor binding to BCL6.

63-71 (canceled)